Infrastructure and equipment for radiation oncology in the spanish national health system: analysis of external beam radiotherapy 2015-2020. by Rodríguez, A. et al.
INFRASTRUCTURE AND EQUIPMENT FOR RADIATION ONCOLOGY IN THE SPANISH NATIONAL HEALTH SYSTEM: ANALYSIS OF 
EXTERNAL BEAM RADIOTHERAPY 2015–2020 
A.Rodríguez1, M.Algara2,3, D.Monge4, J.López-Torrecilla5, F.Caballero4, R.Morera6, R.Escó7, H.Pérez-Montero8, C.Ferrer9, P.C. Lara10,11. On behalf of the 
Spanish Society of Oncology and Radiotherapy (SEOR) Analysis Group12 
1.- Corresponding author. Department of Radiation Oncology. Hospital Ruber Internacional. Address: Calle de la Masó, 38, 28034 Madrid, Spain. e-
mail: arodriguez@ruberinternacional.es 
2.- Department of Radiation Oncology, Hospital de la Esperanza, Parc de Salut Mar, Barcelona, Spain. 
3.- Universitat Pompeu Fabra. Address: San José de la Montaña 12, 08024 Barcelona, Spain.    e-mail: malgara@parcdesalutmar.cat 
4.- Facultad de Medicina. Universidad Francisco de Vitoria. Address: Ctra Pozuelo-Majadahonda km 1.800, 28223 Pozuelo de Alarcón, Madrid, Spain. e-
mail: dmonge@ufv.es; e-mail: fcaballero@ufv.es  
5.- Department of Radiation Oncology, ERESA Hospital General Universitario. Address: Calle de la Casa Misericordia 12, 46014 Valencia, Spain. e-mail: 
jltorrecilla@eresa.com 
6.- Department of Radiation Oncology, Hospital Universitario de La Paz. Address: Paseo de la Castellana 261, 28046 Madrid, Spain. e-mail: 
rosamaria.morera@salud.madrid.org 
7.- Department of Radiation Oncology, Hospital Quirón Zaragoza. Address: Paseo Mariano Renovales 50006, Zaragoza, Spain. e-mail: resco.zar@gmail.com 
8.- Department of Radiation Oncology, Hospital Universitario Doce de Octubre. Address: Avda de Córdoba s/n, 28041 Madrid, Spain. e-mail: 
hectorperezmontero@gmail.com 
9.- Department of Radiation Oncology, Consorcio Hospitalario Provincial de Castellón. Address: Avda del Dr Clará 19, 12002 Castellón, Spain. e-mail: 
ferreralbiach@gmail.com  
10.- Department of Radiation Oncology. Hospital Universitario Dr Negrín. Address: Barranco de la Ballena s/n, 35010 Las Palmas de Gran Canaria, Spain. e-
mael: plara@dcc.ulpgc.es  
11.- Clinical Oncology, Universidad de Las Palmas, Las Palmas, Spain  




Planning for radiation oncology requires reliable estimates of both demand for radiotherapy and availability of technological resources. This study compares 
radiotherapy resources in the 17 regions of the decentralised Spanish National Health System (SNHS).  
MATERIAL AND METHODS 
The Sociedad Española de Oncología Radioterápica (SEOR) performed a cross-sectional survey of all Spanish radiation oncology services (ROS) in 2015. We 
collected data on SNHS radiotherapy units, recording the year of installation, specific features of linear accelerators (LINACs) and other treatment units, and 
radiotherapeutic techniques implemented by region. Any machine over 10 years old or lacking a multileaf collimator or portal imaging system was considered 
obsolete. 
We performed a k-means clustering analysis using the Hartigan-Wong method to test associations between the gross domestic regional product (GDRP), the 
number of LINACs per million population and the percentage of LINACs over 10 years old. 
RESULTS 
The SNHS controls 72 (61%) of the 118 Spanish ROS and has 180 LINACs, or 72.5% of the total public and private resources. The mean rate of LINACs per 
million population is 3.9 for public ROS, and 42% (n=75) of the public accelerators were obsolete in 2015: 61 due to age and 14 due to technological 
capability. There was considerable regional variation in terms of the number and technological capacity of radiotherapy units; correlation between GRDP and 
resource availability was  moderate. 
CONCLUSION 
Despite improvements, new investments are still needed to replace obsolete units and increase access to modern radiotherapy. Regular analysis of ROS in each 
Spanish region is the only strategy for monitoring progress in radiotherapy capacity.  
 
INTRODUCTION 
Planning for radiation oncology requires a reliable estimate of the demand for radiotherapy in a specific population. In Europe, the first attempt [1] to estimate 
infrastructure and planning needs for radiation oncology services (ROS) across the EU was based on a 2003 study from Australia [2], which concluded that 
external beam radiotherapy was indicated for about 52.3% of tumours. More recently, a study based on the work of Barton [3] and analyses from Borràs in the 
ESTRO-HERO (European Society for Radiation Oncology-Health Economics in Radiation Oncology) project [4,5] reported that about 50.5% of new cancer 
cases in Spain require radiotherapy at least once [6]. Additional demand comes from retreatments, re-radiation, non-melanoma skin cancer and benign 
pathologies. The same study estimated that 25%–30% of those with an indication for radiotherapy do not receive it due to geographical and transportation-
related factors; associated comorbidities; patient preferences; inadequate knowledge of radiotherapy among other specialists; and lack of human and physical 
resources, which entail wait lists and delays [4-6]. 
In Spain, the direct costs of cancer stood at EUR 4.82 billion in 2011 – 4.9% of total healthcare expenditure. Radiotherapy cost EUR 248 million, or 5.1% of 
the total direct costs of cancer and 0.25% of total healthcare expenditure [7]. Because substantial capital investments are necessary to purchase radiation 
oncology equipment, this specialty is perceived as relatively expensive, prompting intense debate about its necessity. However, the equipment has a long 
useful life, and the initial layout is balanced by modest costs per patient and service. 
Having assessed the demand for radiotherapy in Spain [6], the next step is to analyse the availability of technical resources, identifying deficits and planning 
for the system’s needs. The Spanish health system is based on the National Health Service (NHS) model, with decentralised administration among 17 regional 
authorities (plus Ceuta and Melilla); these independently administer a common portfolio of health services guaranteed to all citizens, independently of their 
place of residence. Given the differences between other European countries and Spain in demographics, cancer incidence, and available radiotherapy 
equipment, together with the pronounced decentralisation of health services administration, comparing the available resources for external beam radiotherapy 
among the regions – and the factors explaining any differences – is of great interest. 
This study aims to describe the current state of radiotherapy in the Spanish National Health System (SNHS) and in its 17 regions in order to identify system 
needs and propose achievable targets. 
MATERIAL AND METHODS 
The Infrastructure Commission of the Sociedad Española de Oncologia Radioterapica (SEOR) developed a detailed questionnaire on available radiotherapy 
resources (linear accelerators (LINACs) and other equipment, personnel and hospital resources) and sent it to all chiefs of both public and private ROS in 
Spain during the fourth quarter of 2015. 
This analysis focuses only on SNHS resources. 
The questionnaire contained separate items for treatment units other than LINACs, such as cobalt-60 units, surface therapy, portable accelerators, 
tomotherapy, Gammaknife and Cyberknife. SEOR established requirements for minimal acceptability as a multileaf accelerator with an MV portal imaging 
system, while the standard was a multileaf accelerator with cone-beam computed tomography (CT). We considered any machine over 10 years old or lacking 
a multileaf collimator or portal imaging system to be obsolete. 
We recorded the year of installation and specific features for each treatment unit. 
To explore associations with resource availability across regions, we performed a k-means clustering analysis using the Hartigan-Wong method, which 
enables representation of multidimensional data on two axes and definition of the centroid cluster (vector with mean values of each variable). Variables were 
the gross domestic regional product (GDRP) [8], the number of LINACs per million population and the percentage of LINACs over 10 years old. We used 
population data from January 2015 for each region from the Spanish Statistical Office (table 1); data from Andalusia includes the population from the semi-
autonomous cities of Ceuta and Melilla. 




We achieved a 100% response rate to our survey. Our results show that the SNHS controls 72 (61%) of the 118 Spanish ROS and has 180 LINACs, or 72.5% 
of the total public and private resources. The number of inhabitants per ROS ranged from 317,053 in La Rioja to 1,104,479 in the Balearic Islands (table 1). 
The evolution of ROS resources over the past 30 years (1986-2015) is summarised in table 2. 
The mean rate of LINACs per million population is 3.9 for public ROS; only seven regions surpass this average, and none meet the recommendation of 7 
LINACs per million population (figure 1a). Mean daily operating time was 12.32 hours, with all regions operating longer than the typical eight-hour workday 
(figure 1b). 
Of the 180 LINACs available in public centres, 61 (34%) were older than 10 years. The regions with the oldest machines were Galicia, Cantabria and Castilla 
La Mancha, while none of the units used in the Balearic Islands, La Rioja and Navarra were deemed obsolete on this criterion (table 1). Of the 119 machines 
installed within the previous 10 years, 74 (41%) were 6–10 years old, with notable heterogeneity among the regions (table 1). 
Services had 1–5 accelerators each, with most (76%) having 1–2. Just three centres (1.7%) in Andalusia, the Canary Islands and Catalonia had five. Regarding 
the associated technology, 88% (n=159) had a multileaf collimator, 25% (n=45) had a micro-multileaf collimator, and 43% (n=77) had a KV or MV cone-
beam CT (supplemental table online). 
Considering both age- and technology-related criteria for obsolescence, 42% (n=75) of the public accelerators were obsolete in 2015, and 83% will be in 2020. 
Fourteen (12%) LINACs were technologically obsolete, while 105 (88%) of the accelerators installed within the previous 10 years were minimally acceptable, 
and 59.7% (n=71) were standard. 
The results for the ‘other units’ category are as follows.  
 Surface therapy. 12 machines installed from 1975 to 2013 – 4 in Catalonia alone. 
 Tomotherapy. Available in four public centres in Madrid, Castilla-Leon, Castilla-La Mancha and the Basque Country; installed in 2006 or later. 
 Portable accelerators. Two machines: one for intraoperative radiotherapy purchased in 2014 (Gregorio Marañón University Hospital, Madrid), and 
one acquired in 2015 (Hospital Clinic, Barcelona). 
 Intrabeam. Two units from 2013 (Hospital Negrin, Las Palmas) and one from 2015 (Institut Català d’Oncologia, Barcelona). 
 Cyberknife, Gammaknife, proton beam therapy. No units identified. 
With regard to the radiotherapeutic techniques implemented in SNHS centres, 81.9% (n=59 centres) offer intensity modulated radiation therapy (IMRT), 
and 79.1% (n=57) report using some kind of image-guided radiotherapy (IGRT). Volumetric IMRT is performed in 36.1% (n=26). Other techniques used 
include: radiosurgery (34.7%, n=25), brain fractionated stereotactic radiotherapy (43%, n=31), craniospinal radiation (72.2%, n=52), stereotactic body 
radiotherapy (44.4%, n=32), total body irradiation (33.3%, n=24), total skin electron irradiation (6.9%, n=5), intraoperative radiotherapy (9.7%, n=7) and 
paediatric radiotherapy (44.4%, n=32). The distribution of centres offering these techniques is in table 3. 
Other data collected (presented in online supplement) include details for each region regarding LINACs (machine age, technology) and ROS (number of 
machines per centre, types of IMRT offered), as well as an overall description of the external beam radiation techniques offered in public centres. 
The cluster analysis enables graphic representation of the three included variables on the two axes that explain 83.2% of the total variability (figure 2). Spanish 
regions can be classified in four clusters (table 4). Cluster 1 represents regions with the highest GDRP, highest rates of accelerators per million population and 
lowest percentage of obsolete units. Cluster 2 regions have a lower – but still substantial – GDRP and a lower rate of LINACs per million population than the 
(lower GDRP) regions in cluster 3, although more resources in cluster 3 are obsolete. Finally, cluster 4 regions have the lowest GDRP, lowest rate of LINACs 
per million population and the highest percentage of obsolete machines in operation.  
DISCUSSION 
We performed this study to identify gaps and plan for future needs within the comprehensive range of SEOR activities implemented over the past 30 years. 
With full participation from all ROS, we present comparative data on radiotherapy resources for all Spanish regions. These show considerable variability, 
consistent with the variability in resources observed between European countries during the ESTRO-HERO project [9,10]. This pattern suggests that internal 
analyses within national borders are just as important as inter-country comparisons. 
In Spain, the rise in available resources over the past several decades has been notable. The first white paper with data on oncology services, published in 
1986, reported just 50 ROS and 75 megavoltage units [11]. Escó and colleagues [12] also described a situation far from ideal using data from 1999, calling for 
44 additional LINACs and the substitution of obsolete cobalt-60 units. This study was the first to record differences between regions; the most disadvantaged 
were Aragon, Castilla-La Mancha and Murcia, which at the time were still dependent on the central government (decentralisation was not complete until 
2002). 
Before Palacios and colleagues performed the next national analysis using data from 2004 [13], the results of the ESTRO-QUARTS study were published in 
the first attempt to estimate the infrastructure and human resources available for radiotherapy across Europe [1,14]. Investigators based their recommendations 
on objective estimates: 1 LINAC/ 400–450 treatments/year and 1.6–1.9 accelerators/1000 treatments/year. The European average was 5.9 LINACs/million, 
with stark differences between countries. 
Spain did not participate in ESTRO-QUARTS, although a contemporary analysis showed significant growth in infrastructures [13]. The mean number of units 
per million population was 2.7 in public ROS (59% of the total); despite substantial investments, the 177 existing units fell short of the 266–316 estimated as 
necessary. In 2004, 98% of the Spanish ROS performed 3D planning; 17.5%, IMRT; 27%, radiosurgery; and 10%, stereotactic body radiotherapy. 
The last SEOR white paper [15] estimated the deficit in accelerators at 40–60 in 2008, but there were clear improvements over previous reports, and these 
have since continued. The SNHS controlled 57% of the operative ROS in 2008, compared to 61% in our study.  
The ESTRO-HERO project has provided a snapshot of European radiotherapy. While the results reflect progress in meeting previous recommendations [1], 
this study and other international analyse [16] show marked between-country heterogeneity [4,5] with limited access to radiotherapy and targeted treatments in 
some countries.  
In the ESTRO-HERO analysis, Spain (with data from 2011 comprising 112 public and private ROS) has an intermediate rank, with 5.6 LINACs/million 
population and 2.3 LINACs/ROS, for a total of 220 accelerators (< 50% equipped with IMRT) and five remaining cobalt-60 units. Similarly to the QUARTS 
project [1] and other more recent analyses [4,5], HERO results showed wide differences between European countries. Our study confirms that within Spain, 
large variations in available techniques and resources also exist. 
Despite investments in the past several years, the situation in Spain is concerning, particularly given the ageing demography that puts Spain on track to 
become the European country with the oldest population, with implications for rising cancer incidence [18]. Today, even counting LINACs from the private 
sector backed by public provider agreements, there is an evident gap between evidence-based therapeutic demand and available accelerators [19]. The 
introduction of techniques like hypofractionation in breast cancer will also have a long-term impact on the total demand, although for now uptake is slow and 
uneven [20]. More alarming, 42% of the operational stock in 2015 was obsolete. Without new investments, this figure will rise to 83% by 2020 and could 
reach 100% in six regions. 
In practical terms, there are only two options for increasing treatment capacity in ROS: acquire more machines or increase their scheduled use. Extending 
operating hours often entails problems related to the lack of secondary services or auxiliary staff. Moreover, Spanish ROS already operate for around 12 hours 
per day, making it difficult to extend hours longer while still respecting staff and patients’ family commitments. Adding another LINAC to the ROS has the 
benefit of averting interruptions by facilitating patients’ mobility and relocation if another unit breaks down, especially in the case of twin accelerators. Thus, 
extending operating hours is not clearly associated with cost savings compared to purchasing new accelerators.  
The increase in available accelerators has been accompanied by an increase in ROS following the devolution of healthcare administration that began in the 
1990s. Seventy-six per cent of ROS have 1–2 accelerators, reflecting a notable fragmentation and a near absence of subspecialisation (with some exceptions, 
for example reflected in the high number of centres offering paediatric radiotherapy). In the Netherlands, the number of ROS did not grow in 1998–2010, but 
the number of accelerators did. Each centre has, on average, 5.7 accelerators [21], enabling greater subspecialisation by pathology among personnel. 
Moreover, services can replace one or more machines every several years, ensuring the availability of the latest technological developments while still 
exhausting the useful life of each machine. One measure that has helped avoid fragmentation in service provision in this country has been the implementation 
of satellite services affiliated with a large centre. This move has allowed an adequate provision of accelerators in sparsely population area without 
compromising the quality of the service. In Spain, a satellite unit in Tortosa (Tarragona) depends on the ROS in the provincial capital of Reus, enabling care 
of comparable quality for a sparse and extended population [22], similar to another experience in rural Australia [23]. Given the low-density population in 
many regions, additional satellite centres can contribute to ensuring equitable and timely access to high-quality radiotherapy for anyone in Spain. 
The cluster analysis suggests that the availability of therapeutic resources does not depend on the economic resources of regions but rather on policy. Although 
the correlation observed between high GDRP, high rate of LINACs/million population and lower percentage of obsolete machines suggests that the 
availability of economic resources is decisive for ensuring adequate equipment, the cluster analysis reveals that this is not always true. This situation reflects a 
decentralised model of decison-making, resulting in notable variability with regard to radiotherapy resources. 
One limitation of our study, similar to previous analyses [9,10], is that while our data show accelerators’ capacity to perform complex techniques, we cannot 
determine whether the equipment is being used to full capacity. 
Ultimately, although we have observed improved availability of LINACs, our results show great heterogeneity between regions in access to modern 
radiotherapy units. Some regions show deficits in both the number and the technological capacity of their machines. At the same time, the validity of 
traditional indicators like machine age and technological capacity is waning. The advent of high-precision techniques and daily image guidance entails a 
greater use of time and resources, limiting the number of treatments per machine, while the generalised use of moderate hypofractionated treatments for the 
pathologies most frequently treated with radiotherapy shortens treatment course and modifies the capacity of the units. Thus, in the future we will also need to 
monitor incidence data and treatment activity.   
Today, investments should be directed towards replacing units that are obsolete due to age or technology (42% in 2015 and 83% in 2020), increasing the 
availability of and access to advanced techniques that characterise modern radiotherapy. Regular analysis of both public and private sectors in each Spanish 
region is the only strategy for monitoring progress in radiotherapy capacity. When calculating future needs, the role of brachytherapy should not be discounted 
either. Reducing fragmentation in ROS through the pooling of resources and the development of satellite units linked to high-volume services may also be a 
useful strategy for our country. 
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APPENDIX A.  
Members of the Spanish Society of Oncology and Radiotherapy (SEOR) Analysis Group, as authors, can be found, in the online version. 
APPENDIX B. SUPPLEMENTARY DATA 
Supplementary data associated with this article can be found, in the online version. 
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Figure 1a. LINACs per million population and region 




















LINACs per million population
 
Figure 1b.- LINAC daily operating hours in public ROS 
 
Figure 1c.Percentage of public LINACs over 10 years old (2015 data) 
 




































Region ROS Population/ROS Linear 
accelerators 




     n % col N N% col 
Andalusia 13 659,145 32  18 15.1% 14 23.0% 
Aragon 2 658,923 4  3 2.5% 1 1.6% 
Asturias 2 525,614 5  4 3.4% 1 1.6% 
Balearic Islands 1 1,104,479 3  3 2.5% 0 0.0% 
Basque Country 4 547,314 11  8 6.7% 3 4.9% 
Canary Islands 3 700,102 12  9 7.6% 3 4.9% 
Cantabria 1 585,179 3  1 0.8% 2 3.3% 
Castilla la Mancha 2 1,029,595 3  1 0.8% 2 3.3% 
Castilla Leon 5 494,410 10  7 5.9% 3 4.9% 
Catalonia 11 682,555 34  21 17.6% 13 21.3% 
Extremadura 3 364,332 4  3 2.5% 1 1.6% 
Galicia 3 910,782 9  3 2.5% 6 9.8% 
La Rioja 1 317,053 2  2 1.7% 0 0.0% 
Madrid 12 536,416 27  20 16.8% 7 11.5% 
Murcia 2 733,644 5  3 2.5% 2 3.3% 
Navarra 1 640,476 3  3 2.5% 0 0.0% 
Valencian Community 6 830,115 13  10 8.4% 3 4.9% 
Total 72  180  119 100.0% 61 100.0% 
Table 2. - Evolution of radiation oncology services in Spain, 1986–2015 
 
Year  1986 1999 2003 2009 2011  2015 







López  Torrecilla 











LINAC 18 90 132 213 220 248 







  3.9‡ 
   5.3§ 
*2.7 public MV units (includes LINAC + Co) 
†4 public and private MV units (includes LINAC + Co) 
‡3.9 public sector LINACs per million population 


















Table 3. External beam radiation techniques available in public sector radiation oncology services, by Spanish region  
 Radiosurgery Brain FSRT 
Craniospinal 
radiation SBRT TBI TSEI IOR 
Paediatric 
radiotherapy 
 Region N N N N N n N N 
 Andalusia 2 3 7 4 4 0 1 4 
 Aragon 1 1 1 0 0 0 0 1 
 Asturias 0 0 1 0 1 0 0 1 
 Balearic Islands 0 0 1 0 1 0 0 1 
 Basque Country 1 1 2 0 0 0 0 2 
 Canary Islands 3 2 3 2 2 1 1 3 
 Cantabria 1 1 1 1 1 0 0 1 
 Castilla la Mancha 2 2 2 1 0 0 0 2 
 Castilla Leon 1 2 4 2 2 1 0 2 
 Catalonia 2 3 9 6 5 1 0 3 
 Extremadura 0 0 1 0 0 0 0 1 
 Galicia 2 2 2 1 2 0 1 2 
 La Rioja 0 0 1 0 0 0 0 0 
 Madrid 6 8 9 8 3 1 3 4 
 Murcia 2 2 2 2 1 0 0 1 
 Navarra 1 1 1 1 1 0 0 1 
 Valencian Community 1 3 5 4 1 1 1 3 
 Total 25 31 52 32 24 5 7 32 
FSRT: fractionated stereotactic radiotherapy; IOR: intraoperative radiotherapy; SBRT: stereotactic body radiotherapy; TBI: total body irradiation; TSEI: total 




Table 4. Centroids of clusters identified in k-means analysis by means of principal components.  
 
 Cluster  GDRP Rate Rate LINAC > 10 years 
   (Euro)* LINAC† (%) 
      
1 Madrid, Navarra, Basque Country  30.3 7.4 5.4 
2 Aragon, Catalonia, Balearic Islands, La Rioja  25.8 4.8 5.7 
3 Asturias, Canary Islands, Cantabria, Castilla y León, Valencian Community, 
Galicia 
 20.7 5.5 9.4 
4 Andalusia, Castilla la Mancha, Extremadura, Murcia  17.7 4.6 7.8 
      
      
 
GDRP: gross domestic regional product. 
*per 1000. 



























n % row n %row n %row n %row n %row total 
Andalusia 3 9.4% 15 46.9% 10 31.3% 3 9.4% 1 3.1% 32 
Aragon 0 0.0% 3 75.0% 0 0.0% 1 25.0% 0 0.0% 4 
Asturias 3 60.0% 1 20.0% 1 20.0% 0 0.0% 0 0.0% 5 
BalearicIslands 3 100.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 3 
Basque Country 2 18.2% 6 54.5% 3 27.3% 0 0.0% 0 0.0% 11 
CanaryIslands 6 50.0% 3 25.0% 3 25.0% 0 0.0% 0 0.0% 12 
Cantabria 1 33.3% 0 0.0% 2 66.7% 0 0.0% 0 0.0% 3 
Castilla la Mancha 0 0.0% 1 33.3% 2 66.7% 0 0.0% 0 0.0% 3 
Castilla León 4 40.0% 3 30.0% 1 10.0% 2 20.0% 0 0.0% 10 
Catalonia 9 26.5% 12 35.3% 8 23.5% 5 14.7% 0 0.0% 34 
Extremadura 0 0.0% 3 75.0% 1 25.0% 0 0.0% 0 0.0% 4 
Galicia 1 11.1% 2 22.2% 5 55.6% 1 11.1% 0 0.0% 9 
La Rioja 0 0.0% 2 100.0% 0 0.0% 0 0.0% 0 0.0% 2 
Madrid 9 33.3% 11 40.7% 4 14.8% 2 7.4% 1 3.7% 27 
Murcia 0 0.0% 3 60.0% 0 0.0% 2 40.0% 0 0.0% 5 
Navarra 0 0.0% 3 100.0% 0 0.0% 0 0.0% 0 0.0% 3 
















Table 2.Distribution of radiation oncology services (ROS), by number of LINACs (overall and by region) 
Comunidad 
Autónoma 












n %  row n %  row n %  row n %  row n %  row 
 
Andalusia 13 40.63% 13 40.63% 4 12.50% 1 3.13% 1 3.13% 32 
Aragon 2 50.00% 2 50.00% 0 0.00% 0 0.00% 0 0.00% 4 
Asturias 2 40.00% 2 40.00% 1 20.00% 0 0.00% 0 0.00% 5 
BalearicIslands 1 33.33% 1 33.33% 1 33.33% 0 0.00% 0 0.00% 3 
Basque Country 4 36.36% 4 36.36% 2 18.18% 1 9.09% 0 0.00% 11 
CanaryIslands 3 25.00% 3 25.00% 3 25.00% 2 16.67% 1 8.33% 12 
Cantabria 1 33.33% 1 33.33% 1 33.33% 0 0.00% 0 0.00% 3 
Castilla la Mancha 2 66.67% 1 33.33% 0 0.00% 0 0.00% 0 0.00% 3 
Castilla León 5 50.00% 3 30.00% 2 20.00% 0 0.00% 0 0.00% 10 
Catalonia 11 32.35% 11 32.35% 7 20.59% 4 11.76% 1 2.94% 34 
Extremadura 3 75.00% 1 25.00% 0 0.00% 0 0.00% 0 0.00% 4 
Galicia 3 33.33% 3 33.33% 2 22.22% 1 11.11% 0 0.00% 9 
La Rioja 1 50.00% 1 50.00% 0 0.00% 0 0.00% 0 0.00% 2 
Madrid 12 44.44% 9 33.33% 4 14.81% 2 7.41% 0 0.00% 27 
Murcia 2 40.00% 2 40.00% 1 20.00% 0 0.00% 0 0.00% 5 
Navarra 1 33.33% 1 33.33% 1 33.33% 0 0.00% 0 0.00% 3 





























Exac-Trac Vision-RT RT4D orGating 
n %  col n %  col n %  col n %  col n %  col n %  col n %  col n %  col 
23 14.50% 9 20.00% 8 10.40% 12 9.00% 8 11.30% 0 0.00% 1 4.30% 2 6.90% 
Aragon 4 2.50% 1 2.20% 3 3.90% 3 2.30% 1 1.40% 0 0.00% 0 0.00% 0 0.00% 
Asturias 5 3.10% 2 4.40% 3 3.90% 5 3.80% 5 7.00% 2 25.00% 2 8.70% 2 6.90% 
BalearicIsla
nds 
3 1.90% 0 0.00% 0 0.00% 3 2.30% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 
Basque 
Country 
11 6.90% 4 8.90% 8 10.40% 8 6.00% 3 4.20% 0 0.00% 4 17.40% 3 10.30% 
CanaryIslan
ds 
11 6.90% 3 6.70% 8 10.40% 10 7.50% 6 8.50% 0 0.00% 0 0.00% 2 6.90% 
Cantabria 3 1.90% 1 2.20% 1 1.30% 2 1.50% 1 1.40% 1 12.50% 3 13.00% 1 3.40% 
Castilla la 
Mancha 
3 1.90% 1 2.20% 0 0.00% 3 2.30% 0 0.00% 1 12.50% 0 0.00% 1 3.40% 
Castilla 
León 
10 6.30% 2 4.40% 6 7.80% 10 7.50% 6 8.50% 0 0.00% 2 8.70% 0 0.00% 
Catalonia 30 18.90% 6 13.30% 15 19.50% 28 21.10% 16 22.50% 0 0.00% 1 4.30% 9 31.00% 
Extremadur
a 
4 2.50% 0 0.00% 0 0.00% 4 3.00% 1 1.40% 0 0.00% 0 0.00% 0 0.00% 
Galicia 8 5.00% 4 8.90% 2 2.60% 9 6.80% 2 2.80% 1 12.50% 0 0.00% 0 0.00% 
La Rioja 2 1.30% 0 0.00% 1 1.30% 2 1.50% 1 1.40% 0 0.00% 0 0.00% 0 0.00% 
Madrid 23 14.50% 5 11.10% 13 16.90% 16 12.00% 11 15.50% 2 25.00% 9 39.10% 4 13.80% 
Murcia 5 3.10% 4 8.90% 3 3.90% 4 3.00% 3 4.20% 0 0.00% 0 0.00% 0 0.00% 
Navarra 3 1.90% 0 0.00% 1 1.30% 3 2.30% 1 1.40% 0 0.00% 0 0.00% 3 10.30% 
ValencianC
ommunity 
11 6.90% 3 6.70% 5 6.50% 11 8.30% 6 8.50% 1 12.50% 1 4.30% 2 6.90% 
Total 159 100.00% 45 100.00% 77 100.00% 133 100.00% 71 100.00% 8 100.00
% 
23 100.00% 29 100.00% 
 
 
Table 4.Available IMRT and IGRT in public radiation oncology services, by region 
Region 
  
IMRT IGRT StaticIMRT  DynamicIMRT  Volumetric 
IMRT  
n n n n n 
Andalusia 9 10 6 6 4 
Aragon 2 2 1 1 0 
Asturias 1 1 1 1 1 
BalearicIslands 1 1 1 1 1 
Basque Country 3 3 3 0 0 
CanaryIslands 3 3 3 2 2 
Cantabria 1 1 1 1 1 
Castilla la Mancha 2 2 2 1 0 
Castilla Leon 3 4 2 3 2 
Catalonia 11 9 9 9 5 
Galicia 2 1 2 1 0 
La Rioja 1 1 1 1 0 
Madrid 12 11 10 9 8 
Murcia 2 2 2 2 1 
Navarra 1 1 1 1 0 
ValencianCommunity 5 5 5 2 1 
Total 59 57 50 41 26 




















Craniospinalradiation SBRT TBI TSEI IOR Paediatricradiotherapy 
n n n n n n n n 
Andalusia 2 3 7 4 4 0 1 4 
Aragon 1 1 1 0 0 0 0 1 
Asturias 0 0 1 0 1 0 0 1 
BalearicIslands 0 0 1 0 1 0 0 1 
Basque Country 1 1 2 0 0 0 0 2 
CanaryIslands 3 2 3 2 2 1 1 3 
Cantabria 1 1 1 1 1 0 0 1 
Castilla la Mancha 2 2 2 1 0 0 0 2 
Castilla Leon 1 2 4 2 2 1 0 2 
Catalonia 2 3 9 6 5 1 0 3 
Extremadura 0 0 1 0 0 0 0 1 
Galicia 2 2 2 1 2 0 1 2 
La Rioja 0 0 1 0 0 0 0 0 
Madrid 6 8 9 8 3 1 3 4 
Murcia 2 2 2 2 1 0 0 1 
Navarra 1 1 1 1 1 0 0 1 
ValencianCommunity 1 3 5 4 1 1 1 3 
Total 25 31 52 32 24 5 7 32 
FSRT: fractionated stereotactic radiotherapy; IOR: intraoperative radiotherapy; SBRT: stereotactic body radiotherapy; TBI: total 
body irradiation; TSEI: total skin electron irradiation 
